Our Research Excellence

110.17

Research within experimental medicine spans fundamental discovery science to translational approaches, which include early phase clinical trials.

Infrastructure on an unparalleled scale

Our research infrastructure underpins excellent research from invention and early translation (experimental medicine) all the way through to adoption and diffusion.

 



By integrating our basic science and translational research infrastructure to drive forward research, we are able to address healthcare needs and transform the prevention, diagnosis and treatment of diseases for population benefit and wider economic gain.

Excellence in experimental medicine

The MAHSC partnership is a centre of excellence, strength and depth in experimental medicine and translational research.

Our strategic approach to research is through the lens of P4 Medicine: to prevent disease, predict disease progression, personalise treatment pathways and empower patients to participate in their healthcare.

This P4 Medicine approach is applied through all our research and cross-cutting themes (as shown in the diagram below) to provide opportunities for sharing expertise and discoveries, in order to deliver efficient experimental research that maximises synergies across our partnership and accelerates discoveries through to routinely commissioned care.

 

P4 medicine diagram

Strategic aims: research and cross-cutting themes

MAHSC’s research objectives directly address those clinical areas that are the major causes of premature death and high disability in Greater Manchester. These strategic aims are:

  • Musculoskeletal – produce a step change in health outcomes and accelerate discoveries into routinely commissioned care, at scale, in the shortest possible time
  • Cancer Prevention & Early Detection – better understand biology-behaviour-environment interactions, which impact on the approach to endotype discovery, clinical prediction, medication behaviours and early trials
  • Hearing health – improve the lives of people with hearing loss by preventing potentially devastating congenital deafness, diagnosing acquired age-related deficits and developing new treatments
  • Cancer Advanced Radiotherapy – drive national and international innovations and translate advances into patient benefit by predicting disease progression and personalising treatments to ‘Treat Smarter’
  • Respiratory – deliver experimental medicine research to a range of clinical problems in respiratory diseases, from the treatment of complex critically ill patients to the palliation of symptoms in chronic disorders
  • Cancer Precision Medicine – Manchester’s NIHR/CRUK Experimental Cancer Medicines Centre (ECMC) provides a conducive environment to develop and test precision medicine for patient benefit
  • Dermatology – prevent and predict disease progression and personalise treatment for inflammatory skin disease and chronic wounds

Cross-cutting themes:

  • Biomarker Platforms – capitalise on our state-of-the-art infrastructure for biomarker discovery, development and translation, in a way that habitually drives implementation into routinely commissioned healthcare
  • Informatics and data sciences – develop and apply new approaches allowing integration of rich datasets to enable new pathway discovery and allow ongoing calibration of predictive models
  • Rapid Translational Incubator – accelerate biomedical and clinical discoveries through improved efficiency and specific support for early phase trials